A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes NCT07881432 | Eloralintide | Phase 3 | Not yet recruiting | Eli Lilly and Company | 2,115 | Oct 2029 | Nov 17, 2026 |
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk NCT07900633 | None linked | Phase 3 | Not yet recruiting | Eli Lilly and Company | 3,000 | Nov 2029 | Nov 17, 2026 |
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity NCT06745284 | Survodutide | Phase 1 | Active not recruiting | Boehringer Ingelheim | 64 | Nov 1, 2026 | Nov 16, 2026 |
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide NCT07220759 | Cagrilintide | Phase 3 | Active not recruiting | Novo Nordisk A/S | 330 | May 12, 2027 | Nov 16, 2026 |
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) NCT07868835 | VK2735 | Phase 3 | Recruiting | Viking Therapeutics, Inc. | 560 | Jul 2028 | Nov 16, 2026 |
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) NCT07868939 | VK2735 | Phase 3 | Recruiting | Viking Therapeutics, Inc. | 560 | Oct 2028 | Nov 16, 2026 |
A Study Assessing Eloralintide (LY3841136) in Healthy Participants NCT07935304 | Eloralintide | Phase 1 | Not yet recruiting | Eli Lilly and Company | 90 | Apr 2027 | Nov 13, 2026 |
LIVERAGE™ – Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis NCT06632457 | Survodutide | Phase 3 | Recruiting | Boehringer Ingelheim | 1,590 | Jun 5, 2029 | Nov 12, 2026 |
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo NCT07437560 | Melanotan 2 | Phase 2 | Recruiting | Hudson Biotech | 60 | Feb 14, 2027 | Nov 12, 2026 |
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation NCT06299098 | Trevogrumab | Phase 2 | Completed | Regeneron Pharmaceuticals | 1,005 | Jun 16, 2026 | Nov 12, 2026 |
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes NCT05936151 | Retatrutide | Phase 2 | Completed | Eli Lilly and Company | 146 | Oct 1, 2025 | Nov 9, 2026 |
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes NCT07351045 | Enicepatide (CT-388) | Phase 3 | Recruiting | Hoffmann-La Roche | 2,000 | Jul 24, 2028 | Nov 9, 2026 |
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes NCT07351058 | Enicepatide (CT-388) | Phase 3 | Recruiting | Hoffmann-La Roche | 1,600 | Aug 7, 2028 | Nov 9, 2026 |
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants NCT07626515 | Enicepatide (CT-388) | Phase 1 | Active not recruiting | Hoffmann-La Roche | 36 | Apr 8, 2027 | Nov 5, 2026 |
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes NCT07670416 | Enicepatide (CT-388) | Phase 3 | Recruiting | Hoffmann-La Roche | 300 | Feb 24, 2028 | Nov 5, 2026 |
UBT251 Injection Phase II Study (Overweight or Obesity) NCT07177469 | UBT251 | Phase 2 | Completed | The United Bio-Technology (Hengqin) Co., Ltd. | 205 | Oct 22, 2025 | Nov 5, 2026 |
UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study NCT07163624 | UBT251 | Phase 2 | Completed | The United Bio-Technology (Hengqin) Co., Ltd. | 211 | Nov 21, 2025 | Nov 5, 2026 |
UBT251 Injection Phase Ⅲ Study (Overweight or Obesity) NCT07648225 | UBT251 | Phase 3 | Active not recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 600 | Sep 29, 2027 | Nov 5, 2026 |
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide NCT06897475 | Nisotirostide | Phase 2 | Recruiting | Eli Lilly and Company | 200 | May 2027 | Nov 4, 2026 |
A Study of Brenipatide in Participants With Alcohol Use Disorder NCT07219953 | Brenipatide | Phase 3 | Recruiting | Eli Lilly and Company | 1,100 | Apr 2028 | Nov 4, 2026 |
A Study of Brenipatide in Adult Participants With Major Depressive Disorder NCT07412756 | Brenipatide | Phase 3 | Recruiting | Eli Lilly and Company | 1,000 | Feb 2028 | Nov 4, 2026 |
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes NCT07881458 | Eloralintide | Phase 3 | Recruiting | Eli Lilly and Company | 1,000 | Oct 2029 | Nov 4, 2026 |
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes NCT07890376 | LY4086940 | Phase 2 | Not yet recruiting | Eli Lilly and Company | 460 | Jan 2028 | Nov 3, 2026 |
UBT251 Injection Phase II Clinical Study (CKD) NCT07134335 | UBT251 | Phase 2 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 180 | Jul 11, 2030 | Nov 3, 2026 |
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) NCT07145151 | UBT251 | Phase 2 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 156 | Jun 4, 2027 | Nov 3, 2026 |
UBT251 Injection Phase Ⅲ Study (OSA-NPAP) NCT07767942 | UBT251 | Phase 3 | Not yet recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 150 | Sep 2028 | Nov 3, 2026 |
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus NCT06628362 | Enicepatide (CT-388) | Phase 2 | Completed | Carmot Therapeutics, Inc. | 447 | May 29, 2026 | Oct 28, 2026 |
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis NCT06632444 | Survodutide | Phase 3 | Recruiting | Boehringer Ingelheim | 1,800 | Dec 27, 2031 | Oct 28, 2026 |
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events NCT07607587 | Cagrilintide | Phase 1 | Recruiting | Novo Nordisk A/S | 114 | Nov 19, 2027 | Oct 19, 2026 |
A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight NCT07808060 | Eloralintide | Phase 1 | Recruiting | Eli Lilly and Company | 34 | Jun 2027 | Oct 8, 2026 |
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder NCT07219966 | Brenipatide | Phase 3 | Recruiting | Eli Lilly and Company | 1,100 | Apr 2028 | Oct 7, 2026 |
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes NCT07668388 | UBT251 | Phase 2 | Recruiting | Novo Nordisk A/S | 300 | Oct 4, 2027 | Oct 7, 2026 |
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity NCT06525935 | Enicepatide (CT-388) | Phase 2 | Completed | Carmot Therapeutics, Inc. | 469 | Dec 8, 2025 | Oct 5, 2026 |
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight NCT05567796 | Cagrilintide | Phase 3 | Active not recruiting | Novo Nordisk A/S | 3,400 | Oct 30, 2024 | Sep 30, 2026 |
A Study of LY3537031 in Overweight, Obese, and Healthy Participants NCT06606106 | Brenipatide | Phase 1 | Active not recruiting | Eli Lilly and Company | 302 | Nov 2026 | Sep 30, 2026 |
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes NCT06603571 | Eloralintide | Phase 2 | Completed | Eli Lilly and Company | 367 | Jul 1, 2026 | Sep 29, 2026 |
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) NCT06260722 | Retatrutide | Phase 3 | Active not recruiting | Eli Lilly and Company | 1,250 | Aug 27, 2026 | Sep 28, 2026 |
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight NCT07720271 | Amycretin | Phase 3 | Recruiting | Novo Nordisk A/S | 950 | Jun 27, 2028 | Sep 28, 2026 |
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo NCT06131372 | Cagrilintide | Phase 2 | Completed | Novo Nordisk A/S | 626 | Sep 24, 2025 | Sep 24, 2026 |
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone(UNIGUIDE-1) NCT07659574 | UBT251 | Phase 3 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 360 | Sep 24, 2027 | Sep 15, 2026 |
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2) NCT07653477 | UBT251 | Phase 3 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 956 | Feb 29, 2028 | Sep 14, 2026 |
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight NCT06649045 | Orforglipron | Phase 3 | Completed | Eli Lilly and Company | 712 | Jul 21, 2026 | Sep 14, 2026 |
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism NCT07010432 | Cagrilintide | Phase 1 | Recruiting | Novo Nordisk A/S | 144 | May 3, 2028 | Sep 10, 2026 |
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet NCT07184086 | Cagrilintide | Phase 1 | Active not recruiting | Novo Nordisk A/S | 80 | Oct 12, 2027 | Sep 10, 2026 |
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver NCT05202353 | Survodutide | Phase 1 | Active not recruiting | Boehringer Ingelheim | 29 | Jan 6, 2027 | Sep 9, 2026 |
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin NCT06323161 | Cagrilintide | Phase 3 | Completed | Novo Nordisk A/S | 274 | Sep 9, 2025 | Sep 9, 2026 |
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) NCT06926842 | Petrelintide | Phase 2 | Completed | Zealand Pharma | 221 | Aug 13, 2026 | Sep 9, 2026 |
UBT251 Injection Phase Ⅲ Study (OSA-PAP) NCT07806851 | UBT251 | Phase 3 | Not yet recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 150 | Mar 2029 | Sep 8, 2026 |
Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism NCT04648969 | Kisspeptin-10 | Phase 2 | Completed | Stephanie B. Seminara, MD | 18 | Aug 31, 2025 | Aug 26, 2026 |
A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant NCT07710729 | UBT251 | Phase 1 | Recruiting | Novo Nordisk A/S | 40 | Apr 27, 2027 | Aug 25, 2026 |